» Articles » PMID: 23929911

Low Frequency of GITR+ T Cells in Ex Vivo and in Vitro Expanded Treg Cells from Type 1 Diabetic Patients

Overview
Journal Int Immunol
Date 2013 Aug 10
PMID 23929911
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Reported alterations in T(reg) cells from type 1 diabetes (T1D) patients led us to a revision of their phenotypical features compared with controls. A fine cytometric analysis was designed for their characterization, using a panel of markers including FOXP3, CTLA4, glucocorticoid-induced TNFR family related (GITR) and CD127. The frequency of peripheral CD4(+)CD25(hi) T(reg) cells was similar between samples. However, the yield of sorted T(reg) cells was significantly lower in patients than in controls. When comparing the T(reg)-cell phenotype between samples, the only difference concerned the expression of GITR. A significant decrease of GITR(+) cells and GITR mean fluorescence intensity within the T(reg)-cell population, and to a lesser extent in the effector population, was observed in T1D compared with controls. Moreover, GITR expression was analyzed in several conditions of T-cell activation and differences were only observed in T1D T(reg) cells versus controls when responding to sub-optimal stimulation, that is, soluble anti-CD3 or medium alone but not in the presence of anti-CD3-/anti-CD28-coated beads. However, expanded T1D T(reg)-cell-mediated suppression was as efficient as that mediated by their control counterparts, showing no association between their regulatory capacity and the reduced GITR. Our results show a higher susceptibility to apoptosis in patients' versus controls' T(reg) cells, suggesting that GITR is a T(reg)-cell marker that would be primarily involved in T(reg)-cell survival rather than in their suppressor function.

Citing Articles

Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells.

Ipavec N, Rogic Vidakovic M, Markotic A, Pavelin S, Buljubasic Soda M, Soda J Biomedicines. 2024; 12(2).

PMID: 38398067 PMC: 10887021. DOI: 10.3390/biomedicines12020464.


Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.

Thakkar S, Chopra A, Nagendra L, Kalra S, Bhattacharya S touchREV Endocrinol. 2024; 19(2):22-30.

PMID: 38187075 PMC: 10769466. DOI: 10.17925/EE.2023.19.2.7.


PPARs at the crossroads of T cell differentiation and type 1 diabetes.

Riaz F, Wei P, Pan F Front Immunol. 2023; 14:1292238.

PMID: 37928539 PMC: 10623333. DOI: 10.3389/fimmu.2023.1292238.


Glyceryl tribenzoate: A food additive with unique properties to be a substitute for cinnamon.

Pahan S, Dasarathi S, Pahan K J Clin Exp Immunol. 2021; 6(5):367-372.

PMID: 34723288 PMC: 8555914. DOI: 10.33140/jcei.06.05.04.


Activated but functionally impaired memory Tregs are expanded in slow progressors to type 1 diabetes.

Boldison J, Long A, Aitken R, Wilson I, Megson C, Hanna S Diabetologia. 2021; 65(2):343-355.

PMID: 34709423 PMC: 8741669. DOI: 10.1007/s00125-021-05595-0.